Methylation Panel vs 23andMe-Style Genetic Tests
A large share of the people who ask about methylation arrive with a document. It is usually a report generated by uploading the raw data from a consumer ancestry test to a third-party website, and it usually lists a column of gene names — MTHFR, COMT, MTR, MTRR, CBS — beside a column of red, yellow and green, with words like "mutation" and "impaired" next to the red ones. The person wants to know how bad it is. The honest answer is that the document tells them which versions of some enzymes they carry, and almost nothing about whether any of it matters.
This page is the difference between that report and the methylation panel — genotype versus function — and what to do with the report you already have.
What a consumer DNA test measures
A consumer test genotypes several hundred thousand points in the genome where people commonly differ, and reports ancestry, traits and — with a health add-on — a curated set of variants with established clinical meaning. The methylation genes are mostly not in the curated set, and the major consumer companies say why: the variants are common, their effect is small, and knowing them does not change medical care. 23andMe, for one, has explained publicly that it does not report MTHFR for exactly that reason.
The raw data file contains the genotypes anyway, and third-party sites will read them and produce the color-coded report. Three things about that report are worth knowing. The consumer chip is designed for ancestry, and its calls at any individual variant are not laboratory-grade — a small but real error rate applies to every line. The sites label common variants as "mutations," which is technically accurate and practically misleading: a variant carried by forty percent of the population is not a defect. And the interpretation layered on top — which supplements to take, which foods to avoid, which pathways are "blocked" — is not from the genetics literature. It is from the site.
What a blood panel measures
The methylation panel measures the pathway's output. Homocysteine, which rises when the folate–B12 cycle is not keeping up, from whatever cause. Folate and B12, which are the cycle's inputs. B6, which the alternative clearance route needs. And, as context, the genotype for MTHFR and related variants — reported so that a high homocysteine can be interpreted, not as a finding in itself.
The difference is the difference between a blueprint and a gauge. A genotype says how an enzyme is built; it does not say how much substrate it is getting, how much of its product is needed, or whether the other routes are compensating — all of which determine what actually happens. A homocysteine level says whether the pathway is meeting demand. A person with two copies of the MTHFR variant and a normal homocysteine has a pathway that works, whatever the color on the report. A person with no variants and a high homocysteine has a problem the report would have called green.
Why function is what changes decisions
Because every action follows from a measured value. A high homocysteine prompts a search for its cause — a low folate or B12, kidney function, thyroid, a medication — and correction of whatever is found, with a retest to confirm. A low B12 prompts the absorption questions and a route decision. A low folate prompts intake, and in the situations on the B-vitamin forms page, a form decision. None of these is prompted by a genotype, and none of them is changed by one, because the genotype was already expressed in the number.
The consumer report, by contrast, prompts nothing a guideline recognizes. The American College of Medical Genetics recommends against MTHFR testing for clinical purposes. No body recommends acting on COMT, MTR, MTRR or CBS genotypes for supplementation. The "protocols" attached to those reports — methylated vitamins, sulfur restriction, specific sequences of supplements to "open" pathways — have no outcome evidence, and the COMT page covers the most-cited example.
What to do with the report you have
Bring it. It is not useless — it tells us your MTHFR and COMT status without paying for them again, and a clinician who knows you carry two copies of the MTHFR variant will read a borderline homocysteine with that in mind. What it cannot do is substitute for the panel, and what we will not do is act on it alone.
Then get the panel, and let the numbers decide. If homocysteine, folate, B12 and B6 are in range, the report's red lines describe enzymes that are doing their job, and the correct response is to stop worrying about them. If something is out of range, it gets treated on the strength of the measurement, and the genotype is one line in the interpretation. Either way, the supplement protocol that came with the report is not the plan.
Frequently asked questions
The raw data file contains it, and third-party sites will report it. The major consumer companies do not include it in their health reports because it does not change medical care.
Different. A DNA test gives genotype — how enzymes are built. The panel gives function — homocysteine, folate, B12, B6 — which is what changes decisions. The panel includes genotype as context.
They are common variants, carried by large shares of the population. What matters is homocysteine and the vitamin levels. If those are normal, the pathway works.
No. Those protocols have no outcome evidence and no guideline body recommends supplementing on methylation genotypes. Treat what is measured, not what is predicted.
Broadly, with a small but real error rate at any individual variant, because the chips are designed for ancestry rather than clinical genotyping. A laboratory test confirms anything that would matter.
Yes, as context — bring it. We will not act on it alone; the panel's measured values decide.
Where this fits in your plan
The Methylation Panel page covers what is measured; this page is why the measurement outranks the genotype you may already have. Bring the report, get the numbers, let the numbers decide.
We measure first. Then we act.
References
- Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine 2013;15:153–156.
- Tandy-Connor S et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genetics in Medicine 2018;20:1515–1521.
- 23andMe. "Our take on MTHFR" — company blog/customer care statement.
- Refsum H et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clinical Chemistry 2004;50:3–32.
- Green R et al. Vitamin B12 deficiency. Nature Reviews Disease Primers 2017;3:17040.
- Back toMethylation Health Panel
- Methylfolate vs folic acid"Methylated" B vitamins are sold on the MTHFR gene. What the variant actually does, what the trials of folic acid in people who carry it show, when methylfolate is a reasonable choice, and when it is a premium for nothing.Read
- COMT and estrogenThe COMT gene neutralizes estrogen's reactive metabolites, and a common variant slows it. What that means, what is evidence and what is functional-medicine extrapolation, and why it does not decide hormone therapy.Read
- Lab testing: measuring is the first treatmentComprehensive blood, hormone, gut, methylation and glucose testing — the baseline every plan is built on.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.